Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23077008 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Ocular Melanoma With Extraocular Extension;   Recurrent Uveal Melanoma;   Small Size Posterior Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Selumetinib;   Drug: Temozolomide;   Drug: Dacarbazine;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment

Indicates status has not been verified in more than two years